What is Zacks Research’s Forecast for WST Q4 Earnings?

West Pharmaceutical Services, Inc. (NYSE:WST) – Equities research analysts at Zacks Research raised their Q4 2027 earnings estimates for shares of West Pharmaceutical Services in a research note issued on Thursday, January 22nd. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings of $2.26 per share for the quarter, up from their previous estimate of $2.20. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.29. The business had revenue of $804.60 million during the quarter, compared to analysts’ expectations of $788.42 million. West Pharmaceutical Services had a net margin of 16.29% and a return on equity of 18.16%. The business’s quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the company posted $1.85 earnings per share.

WST has been the subject of a number of other research reports. Morgan Stanley initiated coverage on West Pharmaceutical Services in a research report on Monday, December 1st. They set an “equal weight” rating and a $285.00 price target for the company. Wall Street Zen raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Saturday, December 20th. Weiss Ratings reiterated a “hold (c)” rating on shares of West Pharmaceutical Services in a research report on Friday, January 9th. KeyCorp raised their price target on shares of West Pharmaceutical Services from $325.00 to $350.00 and gave the stock an “overweight” rating in a research report on Friday, October 24th. Finally, Barclays upped their price objective on shares of West Pharmaceutical Services from $275.00 to $325.00 and gave the company an “equal weight” rating in a report on Monday, October 27th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $335.78.

West Pharmaceutical Services Price Performance

Shares of WST opened at $236.78 on Monday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.87 and a quick ratio of 2.18. The company’s fifty day moving average price is $270.73 and its 200-day moving average price is $261.11. West Pharmaceutical Services has a 1-year low of $187.43 and a 1-year high of $348.90. The firm has a market capitalization of $17.03 billion, a PE ratio of 35.08, a price-to-earnings-growth ratio of 3.26 and a beta of 1.17.

West Pharmaceutical Services Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 4th. Shareholders of record on Wednesday, January 28th will be given a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 0.4%. The ex-dividend date is Wednesday, January 28th. West Pharmaceutical Services’s dividend payout ratio is currently 13.04%.

Hedge Funds Weigh In On West Pharmaceutical Services

Institutional investors have recently made changes to their positions in the company. CYBER HORNET ETFs LLC purchased a new stake in West Pharmaceutical Services during the second quarter worth $25,000. Vermillion & White Wealth Management Group LLC increased its holdings in West Pharmaceutical Services by 193.9% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 144 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 95 shares in the last quarter. SJS Investment Consulting Inc. raised its position in shares of West Pharmaceutical Services by 1,842.9% in the third quarter. SJS Investment Consulting Inc. now owns 136 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 129 shares during the period. CVA Family Office LLC boosted its stake in shares of West Pharmaceutical Services by 573.3% during the 2nd quarter. CVA Family Office LLC now owns 202 shares of the medical instruments supplier’s stock worth $44,000 after acquiring an additional 172 shares in the last quarter. Finally, Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of West Pharmaceutical Services during the 3rd quarter worth about $47,000. 93.90% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Citi initiated coverage with a Buy, providing an independent institutional endorsement that can support demand for the shares and reinforce confidence in West’s strategic positioning. West Pharmaceutical Services (WST) Gets a Buy from Citi
• Positive Sentiment: Zacks Research upgraded WST to a Strong-Buy (Zacks Rank #1) and raised earnings estimates across multiple quarters and fiscal years, signaling improved analyst expectations for revenue/profitability and providing a near-term catalyst for buy-side interest. All You Need to Know About West Pharmaceutical (WST) Rating Upgrade to Strong Buy
• Positive Sentiment: Product launch: West unveiled the Synchrony S1 prefillable syringe at Pharmapack 2026 — a move that targets biologics, vaccines and home-care use and could expand its addressable market in combination products and drug-delivery systems. WST Launches Synchrony S1 Prefillable Syringe at Pharmapack
• Neutral Sentiment: Analysis piece discusses West’s expansion into biologic syringe systems and whether that reshapes its combination‑product competitive edge — useful context for investors assessing long‑term growth but not an immediate earnings surprise. Does West Pharmaceutical (WST) Expanding Into Biologic Syringe Systems Reshape Its Combination-Product Edge?
• Neutral Sentiment: Zacks included WST on thematic lists (top medical-supply names and income-stock lists) — a visibility boost that may attract income and thematic investors but is less of an immediate price catalyst than upgrades or product news. 4 Medical Supply Stocks Poised to Gain

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.